Corvus Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., May 20, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership team will conduct one-on-one meetings with investors and present a corporate overview at the 2026 Jefferies Global Healthcare Conference, to be held in New York, NY, and the Goldman Sachs 47th Annual Global Healthcare Conference, to be held in Miami, FL. The Jefferies presentation is scheduled for Wednesday, June 3, 2026 at 3:45 PM ET, and the Goldman Sachs presentation is scheduled for Monday, June 8, 2026 at 11:20 AM ET.

GlobeNewsWire • May 20, 2026

Corvus Pharmaceuticals: The Market Is Pricing Atopic Dermatitis Success Too Early

Corvus Pharmaceuticals, Inc. remains a Sell as its valuation has run ahead of fundamentals following encouraging but limited Phase 1 AD data. Soquelitinib shows activity in atopic dermatitis, but questions remain on safety, durability, and efficacy in broader populations versus established treatments. My DCF analysis yields a fair value of $10.07/share, implying 16% downside from current levels, with significant future cash needs likely requiring dilution.

Seeking Alpha • May 19, 2026

Corvus Pharmaceuticals, Inc. (CRVS) Shareholder/Analyst Call Transcript

Corvus Pharmaceuticals, Inc. (CRVS) Shareholder/Analyst Call Transcript

Seeking Alpha • May 14, 2026

Corvus Pharmaceuticals Presents Soquelitinib Phase 1 Atopic Dermatitis Data at the Society for Investigative Dermatology (SID) Annual Meeting

New immunologic and biomarker data supports the potential of ITK inhibition with soquelitinib to increase persistent Treg cells and influence multiple inflammatory pathways. Data supports potential for soquelitinib to rebalance the immune system and produce drug-free remissions following discontinuation of therapy Immunologic markers consistent with soquelitinib's novel mechanism of action and clinical results SID data included in late-breaking oral presentation; company to review data at investor and analyst meeting today at 1:30 pm ET (12:30 pm CT) SOUTH SAN FRANCISCO, Calif.

GlobeNewsWire • May 14, 2026

Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2026 Financial Results

Soquelitinib clinical development for atopic dermatitis advancing with Phase 1 cohort 4 positive data and initiation of Phase 2 trial during the quarter New immunologic and biomarker data supporting the potential for drug-free remissions with soquelitinib to be presented at Society for Investigative Dermatology (SID) annual meeting Company hosting investor and analyst meeting to review SID data on May 14, 2026 at 1:30 pm ET (12:30 pm CT) SOUTH SAN FRANCISCO, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the first quarter ended March 31, 2026.

GlobeNewsWire • May 7, 2026

Corvus Pharmaceuticals Appoints Andrew C. Chan, M.D.

SOUTH SAN FRANCISCO, Calif., April 23, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, announced today that Andrew C. Chan, M.D., Ph.D., has been appointed to the Company's Board of Directors. Dr. Chan recently served as Senior Vice President, Research Biology during a distinguished 25 year career at Genentech. In this role, he led biological research across all therapeutic areas, contributing to the development of several FDA-approved medicines for oncology, neurology and immunology.

GlobeNewsWire • Apr 23, 2026

Corvus Pharmaceuticals to Host Investor and Analyst Meeting on May 14, 2026 to Highlight Soquelitinib Data Being Presented at the Society for Investigative Dermatology (SID) Annual Meeting

Two oral presentations including late-breaker at SID  Data will cover Phase 1 clinical trial of soquelitinib for atopic dermatitis, including new immunologic and biomarker data supporting drug-free remissions Investor and analyst meeting scheduled for 1:30 pm ET (12:30 pm CT) on May 14, 2026 Company to report first quarter 2026 financial results on May 7, 2026 SOUTH SAN FRANCISCO, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, announced today that it will host an in-person and virtual investor and analyst meeting on May 14, 2026 to highlight soquelitinib data being presented at the Society for Investigative Dermatology (SID) Annual Meeting, which is taking place May 13-16, 2026 in Chicago.

GlobeNewsWire • Apr 21, 2026

Corvus Pharmaceuticals, Inc. (CRVS) Q4 2025 Earnings Call Transcript

Corvus Pharmaceuticals, Inc. (CRVS) Q4 2025 Earnings Call Transcript

Seeking Alpha • Mar 13, 2026

Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

Announced data from cohort 4 of soquelitinib atopic dermatitis Phase 1 trial demonstrating positive safety and efficacy results, including in patients who have received prior systemic therapy

GlobeNewsWire • Mar 12, 2026

Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026

Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT

GlobeNewsWire • Mar 5, 2026